Veos Pharmaceuticals

Startup
Summarized by Halo AI

Veos Pharmaceuticals is a Madrid-based biotechnology company providing science-backed solutions in human health, agriculture, and environmental systems. Operating since 2023, it delivers over 40 products through a vertically integrated model.

Founded & HQ
Madrid, Spain
Company size
1-10 employees
Funding
~$1M
IP status
1 grant confirmed
Activity highlights
Secured funding under the Innowwide Call 4 programme of the Eureka Network to expand agricultural biotechnology platform BioPropello™ into the Japanese market in June 2026.

Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.

The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.

AI summary generated on Jun 22, 2026
OpenAlexOpenAlex

For general inquiries

Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.

Looking for

Sponsored researchCo-developmentSupply/purchaseLicensingEquity investmentPilot or trial engagement

Key links

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.